Ireland· IE-PA-EU/1/13/818/001-002
Bosulif 100 mg film-coated tablets
A bosutinib product containing bosutinib monohydrate, registered in Ireland by Pfizer Europe MA EEIG. The same ATC class is registered in 15 of our 19 countries.
Checked against HPRA (Ireland) on
Informational only — not a medical device.
Where it is registered
Bosutinib is registered in 15 of 19 countries.
Countries holding a registration under ATC L01EA04 (bosutinib), each read from that country’s own register.
- This record: Ireland, from HPRA (Ireland)
- 8 of them publish a price we can compare per daily dose
Bosutinib · ATC L01EA04
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of bosutinib costs, country by country.
Normalised to the WHO defined daily dose (0.4 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Bosutinib · price per daily dose (0.4 g)
USD · FX 28 Sept 2026
- CH Switzerland$65.58
The record
At a glance
HPRA (Ireland)- Active substance
- Bosutinib monohydrate
- Manufacturer
- Pfizer Europe MA EEIG
- Country
- Ireland (IE)
- ATC code
- L01EA04
- ATC class
- Bosutinib
- Defined daily dose
- 0.4 g, O
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/13/818/001-002
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
469 interactions on record for bosutinib.
Graded by severity as the source publishes them — 159 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Bosutinib · interactions on record
469 records
- 159 severe
- 307 moderate
- 3 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- DolasetronA04AA04severe
- AprepitantA04AD12severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01EA04
Bosutinib, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b22759d9-554c-4c7c-993e-4e7fcfa2b79d GET /v1/drugs/b22759d9-554c-4c7c-993e-4e7fcfa2b79d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"L01EA04"
],
"strength": null,
"pa_number": "EU/1/13/818/001-002",
"substances": [
"Bosutinib monohydrate"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": null,
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": "IC0169-024-003"
}See everything about bosutinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.